Inhibitor development risk similar for factor VIII products

Inhibitor development risk similar for factor VIII products
For children with severe hemophilia A, the risk of inhibitor development is similar with plasma-derived and recombinant factor VIII products and is not affected by von Willebrand factor content or by switching among products, according to research published in the Jan. 17 issue of the New England Journal of Medicine.

(HealthDay)—For children with severe hemophilia A, the risk of inhibitor development is similar with plasma-derived and recombinant factor VIII products and is not affected by von Willebrand factor content or by switching among products, according to research published in the Jan. 17 issue of the New England Journal of Medicine.

Samantha C. Gouw, M.D., Ph.D., of the University Medical Center Utrecht in the Netherlands, and colleagues examined the effects of specific product administration on the development of clinically relevant inhibitory antibodies in 574 consecutive children with severe hemophilia A, born from 2000 to 2010.

The researchers found that the cumulative incidence of inhibitory antibody development was 32.4 percent, while a high-titer inhibitory antibody, defined as a peak titer of at least 5 Bethesda units/mL, had a cumulative incidence of 22.4 percent. The risk of inhibitor development was similar for plasma derived or recombinant products. Among the recombinant products, however, second-generation full-length products correlated with a significantly increased risk of inhibitor development (adjusted hazard ratio, 1.6) compared with third-generation products derived from the full-length sequence of human factor VIII. The risk of inhibitor development was not associated with the von Willebrand factor content of products or switching between products.

"Recombinant and plasma-derived factor VIII products conferred similar risks of inhibitor development, and the content of von Willebrand factor in the products and switching among products were not associated with the risk of inhibitor development," the authors write. "Second-generation full-length recombinant products were associated with an increased risk, as compared with third-generation ."

The study was funded by Bayer Healthcare and Baxter BioScience; several authors disclosed financial ties to pharmaceutical companies, including Bayer and Baxter.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Von Willebrand factor linked to bleeding complications

Mar 09, 2012

(HealthDay) -- Oral anticoagulation (OAC)-treated patients with high levels of von Willebrand factor (VWF) have elevated risks of bleeding complications and cardiovascular and all-cause mortality, according ...

Major illness increases venous thrombosis risk

Nov 03, 2012

(HealthDay)—People with major illnesses, including liver or kidney disease, rheumatoid arthritis, multiple sclerosis, heart failure, hemorrhagic stroke, or arterial thrombosis, have an increased risk of ...

Hep B screening urged before TNF-alpha inhibitor therapy

Jul 01, 2012

(HealthDay) -- All patients with psoriasis should be screened for hepatitis B surface antigen and hepatitis B core antibody prior to the initiation of tumor necrosis factor-alpha inhibitor therapy, according ...

Recommended for you

Electronic health records tied to shorter time in ER

Sep 19, 2014

(HealthDay)—Length of emergency room stay for trauma patients is shorter with the use of electronic health records, according to a study published in the September issue of the Journal of Emergency Nursing.

CDC: Almost everyone needs a flu shot

Sep 19, 2014

(HealthDay)—Less than half of all Americans got a flu shot last year, so U.S. health officials on Thursday urged that everyone 6 months and older get vaccinated for the coming flu season. "It's really unfortunate ...

User comments